CytoMed Therapeutics GDTC Income Statement (2021-2026)

NASDAQ GDTC
$0.90 +0.06 (+6.75%)
At close: Oct 1, 2026 · 4:00 PM EDT
Reported Financials

CytoMed Therapeutics Quarterly Income Statement

Periods 8 quarters
Latest Jun 2026

CytoMed Therapeutics income statement data for the quarter ended Jun 2026. This income statement covers 8 quarters of results from Dec 2021 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Income Statement Dec2021 Dec2022 Dec2023 Jun2024 Dec2024 Jun2025 Dec2025 Jun2026
Revenue & Cost
Revenue 0.01M0.01M
Non-interest income
Service Charges 0.06M0.03M
Income - Equity -0.02M-0.02M-0.00M
Non-Interest Income -0.02M-0.02M0.06M0.03M-0.00M
Operating Items
Research & DevelopmentR&D 0.28M0.31M
Amortization - Intangibles 321.000.01M
Depreciation & Amortization - TotalDep. & Amort. (Tot) 0.08M0.09M
Share-based Compensation (IS) 0.36M
Restructuring CostsRestructuring 0.06M0.06M
Other Operating ExpensesOther Opex 0.01M
Operating ExpensesOpex 0.40M
Additional items
Shares Outstanding 11.65M
Shares Outstanding (Diluted)Shares Outstanding (Dil.) 11.65M
Shares Outstanding (Entity)Shares Outstanding (Entity.) 7.48M7.92M11.54M11.54M11.83M

CytoMed Therapeutics Income Statement API

Pull CytoMed Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=GDTC&statement=IS&frequency=Quarter&period=all&api_key=YOUR_API_KEY